A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas

Página do item simplificado
dc.contributor.authorDi Filippo, Leonardo Delello [UNESP]
dc.contributor.authorde Carvalho, Suzana Gonçalves [UNESP]
dc.contributor.authorDuarte, Jonatas Lobato [UNESP]
dc.contributor.authorLuiz, Marcela Tavares [UNESP]
dc.contributor.authorPaes Dutra, Jessyca Aparecida [UNESP]
dc.contributor.authorde Paula, Geanne Aparecida [UNESP]
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.authorConde, João
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade NOVA de Lisboa
dc.date.accessioned2023-07-29T16:15:04Z
dc.date.available2023-07-29T16:15:04Z
dc.date.issued2023-06-01
dc.description.abstractGliomas are the most common type of brain cancer, and among them, glioblastoma multiforme (GBM) is the most prevalent (about 60% of cases) and the most aggressive type of primary brain tumor. The treatment of GBM is a major challenge due to the pathophysiological characteristics of the disease, such as the presence of the blood-brain barrier (BBB), which prevents and regulates the passage of substances from the bloodstream to the brain parenchyma, making many of the chemotherapeutics currently available not able to reach the brain in therapeutic concentrations, accumulating in non-target organs, and causing considerable adverse effects for the patient. In this scenario, nanocarriers emerge as tools capable of improving the brain bioavailability of chemotherapeutics, in addition to improving their biodistribution and enhancing their uptake in GBM cells. This is possible due to its nanometric size and surface modification strategies, which can actively target nanocarriers to elements overexpressed by GBM cells (such as transmembrane receptors) related to aggressive development, drug resistance, and poor prognosis. In this review, an overview of the most frequently overexpressed receptors in GBM cells and possible approaches to chemotherapeutic delivery and active targeting using nanocarriers will be presented.en
dc.description.affiliationSchool of Pharmaceutical Sciences São Paulo State University (UNESP), Araraquara
dc.description.affiliationToxOmics NOVA Medical School Faculdade de Ciências Médicas NMS|FCM Universidade NOVA de Lisboa
dc.description.affiliationUnespSchool of Pharmaceutical Sciences São Paulo State University (UNESP), Araraquara
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipH2020 European Research Council
dc.description.sponsorshipIdFAPESP: #2020/12622-0
dc.description.sponsorshipIdFAPESP: #2022/06224-7
dc.description.sponsorshipIdH2020 European Research Council: 848325
dc.identifierhttp://dx.doi.org/10.1016/j.mtbio.2023.100671
dc.identifier.citationMaterials Today Bio, v. 20.
dc.identifier.doi10.1016/j.mtbio.2023.100671
dc.identifier.issn2590-0064
dc.identifier.scopus2-s2.0-85160439097
dc.identifier.urihttp://hdl.handle.net/11449/250000
dc.language.isoeng
dc.relation.ispartofMaterials Today Bio
dc.sourceScopus
dc.subjectBrain cancer
dc.subjectDrug delivery
dc.subjectGlioma
dc.subjectMolecular machinery
dc.subjectNanomedicine
dc.subjectTarget delivery
dc.titleA receptor-mediated landscape of druggable and targeted nanomaterials for gliomasen
dc.typeResenha
unesp.author.orcid0000-0002-7276-3686[3]
unesp.author.orcid0000-0002-8637-6783[6]
unesp.author.orcid0000-0002-6698-0545[7]
unesp.author.orcid0000-0001-8422-6792[8]
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos

Coleções

Araraquara - FCF - Faculdade de Ciências Farmacêuticas